JP2016510309A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510309A5 JP2016510309A5 JP2015547567A JP2015547567A JP2016510309A5 JP 2016510309 A5 JP2016510309 A5 JP 2016510309A5 JP 2015547567 A JP2015547567 A JP 2015547567A JP 2015547567 A JP2015547567 A JP 2015547567A JP 2016510309 A5 JP2016510309 A5 JP 2016510309A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- mer
- axl
- tyro3
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims 56
- 101150098329 Tyro3 gene Proteins 0.000 claims 24
- 239000003112 inhibitor Substances 0.000 claims 20
- 239000000562 conjugate Substances 0.000 claims 16
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 10
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims 10
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 239000000863 peptide conjugate Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102220529619 ATP synthase subunit a_H61Y_mutation Human genes 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102220567663 Matrilysin_V92A_mutation Human genes 0.000 claims 1
- 102220567664 Matrilysin_V92D_mutation Human genes 0.000 claims 1
- 102220567707 Matrilysin_V92G_mutation Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 102220344853 c.257A>G Human genes 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102200005981 rs104894561 Human genes 0.000 claims 1
- 102200045113 rs104894683 Human genes 0.000 claims 1
- 102200032988 rs104894959 Human genes 0.000 claims 1
- 102220219923 rs1060503389 Human genes 0.000 claims 1
- 102220218297 rs1060503453 Human genes 0.000 claims 1
- 102220012991 rs111033344 Human genes 0.000 claims 1
- 102220003706 rs137852315 Human genes 0.000 claims 1
- 102200063970 rs150190385 Human genes 0.000 claims 1
- 102220265708 rs1555054052 Human genes 0.000 claims 1
- 102220245301 rs1555596673 Human genes 0.000 claims 1
- 102220005514 rs3180281 Human genes 0.000 claims 1
- 102220005273 rs33915112 Human genes 0.000 claims 1
- 102220005263 rs33948578 Human genes 0.000 claims 1
- 102200082936 rs33950507 Human genes 0.000 claims 1
- 102220005408 rs33984024 Human genes 0.000 claims 1
- 102220012959 rs377052919 Human genes 0.000 claims 1
- 102220135902 rs61731470 Human genes 0.000 claims 1
- 102220072209 rs727505205 Human genes 0.000 claims 1
- 102220098139 rs878852992 Human genes 0.000 claims 1
- 102220099378 rs878854009 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737276P | 2012-12-14 | 2012-12-14 | |
| US61/737,276 | 2012-12-14 | ||
| PCT/US2013/074786 WO2014093690A1 (en) | 2012-12-14 | 2013-12-12 | Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098435A Division JP6832887B2 (ja) | 2012-12-14 | 2018-05-23 | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510309A JP2016510309A (ja) | 2016-04-07 |
| JP2016510309A5 true JP2016510309A5 (enExample) | 2017-02-02 |
| JP6345690B2 JP6345690B2 (ja) | 2018-06-20 |
Family
ID=50934967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547567A Active JP6345690B2 (ja) | 2012-12-14 | 2013-12-12 | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 |
| JP2018098435A Expired - Fee Related JP6832887B2 (ja) | 2012-12-14 | 2018-05-23 | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098435A Expired - Fee Related JP6832887B2 (ja) | 2012-12-14 | 2018-05-23 | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9822347B2 (enExample) |
| EP (2) | EP3326622B1 (enExample) |
| JP (2) | JP6345690B2 (enExample) |
| AU (3) | AU2013359179B2 (enExample) |
| CA (1) | CA2894539C (enExample) |
| DK (2) | DK3326622T3 (enExample) |
| ES (2) | ES2862335T3 (enExample) |
| FI (1) | FI2931265T6 (enExample) |
| NO (1) | NO3049208T3 (enExample) |
| PT (2) | PT3326622T (enExample) |
| WO (1) | WO2014093690A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| RU2556822C2 (ru) * | 2010-01-22 | 2015-07-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Ингибирование axl сигнализации в антиметастатической терапии |
| WO2013090776A1 (en) | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| FI2931265T6 (fi) | 2012-12-14 | 2023-05-23 | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa | |
| CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| EP3233902B1 (en) * | 2014-12-18 | 2020-09-09 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
| KR20200085307A (ko) * | 2017-11-04 | 2020-07-14 | 아라바이브 바이올로직스, 인크. | Axl 유인 수용체를 이용한 전이성 암의 치료 방법 |
| JP2024533362A (ja) * | 2021-09-11 | 2024-09-12 | アラヴィヴ インコーポレイテッド | Ａｘｌデコイ受容体を一次治療として使用する局所進行又は転移性膵臓腺がんを治療する方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5538861A (en) | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
| US20030166107A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| AU2003304180A1 (en) | 2002-09-24 | 2005-01-04 | Dow, Kenneth, Centocor, Inc. | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses |
| US20070142273A1 (en) | 2003-04-18 | 2007-06-21 | Sherif Daouti | Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis |
| JP2005278631A (ja) | 2004-03-04 | 2005-10-13 | National Institute Of Advanced Industrial & Technology | Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法 |
| CA2630475A1 (en) | 2004-11-24 | 2006-06-01 | The Regents Of The University Of Colorado | Mer diagnostic and therapeutic agents |
| US7932032B2 (en) | 2005-05-02 | 2011-04-26 | Toray Industries, Inc. | Method for diagnosing esophageal cancer |
| US8168415B2 (en) * | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
| CN101679313A (zh) | 2007-04-13 | 2010-03-24 | 休普基因公司 | 用于治疗癌症或过度增殖性疾病的axl激酶抑制剂 |
| CA2692320A1 (en) | 2007-07-02 | 2009-01-08 | Wyeth | Methods of treating bone disorders with modulators of axl |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| CA2747678A1 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| KR20120035145A (ko) | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| RU2556822C2 (ru) * | 2010-01-22 | 2015-07-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Ингибирование axl сигнализации в антиметастатической терапии |
| AU2011326164B2 (en) | 2010-11-08 | 2016-05-05 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| WO2013090776A1 (en) * | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| US20150315552A1 (en) | 2012-12-14 | 2015-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL Signaling in Primary Tumor Therapy |
| FI2931265T6 (fi) | 2012-12-14 | 2023-05-23 | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa | |
| US20160266136A1 (en) * | 2013-08-30 | 2016-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | High-affinity binding to gas6 |
| CA2909669C (en) * | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| EP3233902B1 (en) * | 2014-12-18 | 2020-09-09 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
-
2013
- 2013-12-12 FI FIEP13862780.7T patent/FI2931265T6/fi active
- 2013-12-12 US US14/650,854 patent/US9822347B2/en active Active
- 2013-12-12 AU AU2013359179A patent/AU2013359179B2/en not_active Ceased
- 2013-12-12 WO PCT/US2013/074786 patent/WO2014093690A1/en not_active Ceased
- 2013-12-12 EP EP17196662.5A patent/EP3326622B1/en active Active
- 2013-12-12 JP JP2015547567A patent/JP6345690B2/ja active Active
- 2013-12-12 ES ES17196662T patent/ES2862335T3/es active Active
- 2013-12-12 DK DK17196662.5T patent/DK3326622T3/da active
- 2013-12-12 EP EP13862780.7A patent/EP2931265B3/en active Active
- 2013-12-12 PT PT171966625T patent/PT3326622T/pt unknown
- 2013-12-12 PT PT138627807T patent/PT2931265T/pt unknown
- 2013-12-12 CA CA2894539A patent/CA2894539C/en active Active
- 2013-12-12 DK DK13862780.7T patent/DK2931265T6/da active
- 2013-12-12 ES ES13862780T patent/ES2665323T7/es active Active
-
2014
- 2014-06-30 NO NO14741534A patent/NO3049208T3/no unknown
-
2017
- 2017-10-13 US US15/783,850 patent/US11136563B2/en not_active Expired - Fee Related
- 2017-12-06 AU AU2017272193A patent/AU2017272193A1/en not_active Abandoned
-
2018
- 2018-05-23 JP JP2018098435A patent/JP6832887B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-02 AU AU2019210662A patent/AU2019210662B2/en not_active Ceased
-
2021
- 2021-09-02 US US17/465,203 patent/US20220220458A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510309A5 (enExample) | ||
| JP2016000731A5 (enExample) | ||
| WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
| WO2013011076A3 (en) | Tnf -alpha antigen- binding proteins with increased fcrn binding | |
| WO2018098363A3 (en) | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x | |
| WO2021041715A3 (en) | Compositions including igg fc mutations and uses thereof | |
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| NL300919I2 (nl) | Brodalumab | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| JP2014043446A5 (enExample) | ||
| JP2019514361A5 (enExample) | ||
| WO2014074532A3 (en) | Compositions and methods for modulating cell signaling | |
| JP2015212284A5 (enExample) | ||
| HK1198832A1 (en) | Fn14 binding proteins and uses thereof | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| EA201390923A1 (ru) | Модифицированное антитело с улучшенным полупериодом существования | |
| EA030777B9 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| JP2017518072A5 (enExample) | ||
| WO2013024059A3 (en) | Modified single variable domain antibodies with reduced binding to anti-drug-antibodies | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| WO2012088247A3 (en) | Anti-c5/c5a/c5adesr antibodies and fragments | |
| JP2014518898A5 (enExample) | ||
| JP2017529870A5 (enExample) | ||
| MX2021003636A (es) | Receptor antigenico quimerico. | |
| WO2007146401A3 (en) | Denatured collagen peptides and uses thereof |